A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease

Kenya Nishioka, Mounir Kefi, Barbara Jasinska-Myga, Christian Wider, Carles Vilariño-Güell, Owen A Ross, Michael G. Heckman, Lefkos T. Middleton, Lianna Ishihara-Paul, Rachel A. Gibson, Rim Amouri, Samia Ben Yahmed, Samia Ben Sassi, Mourad Zouari, Ghada El Euch, Matthew J. Farrer, Faycal Hentati

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Genetic classification of Parkinson's disease (PD) subtypes may become the preferred diagnostic tool for neurologists. Herein we compare clinical features from a large cohort of patients with familial PD of unknown aetiology or attributable to distinct genetic forms. Comprehensive neurological examinations were performed in 231 familial PD patients from Tunisia. Analysis was previously performed to screen for mutations in leucine rich repeat kinase 2 (LRRK2), PTEN induced kinase 1 (PINK1) and parkin (PRKN). Clinical features were compared between patients with genetically undefined PD (n107) and those with LRRK2 (n=73) and PINK1 (n42) mutations using regression analyses adjusted for gender, age of onset and disease duration. PRKN cases (n9) were too few for meaningful statistical analysis. In comparison with genetically undefined patients, LRRK2 mutation carriers had more severe motor symptoms (median Unified Parkinson's Disease Rating Scale scores w1.6 times higher, p<0.001), a higher rate of dyskinesia (OR 4.21, p0.002) and use of dopamine agonists (OR 3.64, p<0.001), and less postural tremor (OR 0.21, p<0.001). PINK1 mutation carriers presented an increased rate of drug induced dyskinesia (OR 3.81, p=0.007) and a lower rate of postural tremor (OR 0.16, p<0.001) than genetically undefined patients. As expected, PINK1 patients had younger ages and ages at disease onset, and a longer disease duration compared with LRRK2 mutation carriers and genetically undefined patients. Clinical differences between LRRK2, PINK1 and genetically undefined familial PD appear more pronounced than previously appreciated, and may prove useful in clinical practice. As future therapies are targeted to specific protein abnormalities, identifying the genetic causes and associated clinical and pathological features will determine diagnosis, preventative medicine and drug intervention strategies.

Original languageEnglish (US)
Pages (from-to)391-395
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume81
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Leucine
Parkinson Disease
Phosphotransferases
Mutation
Tremor
Age of Onset
Drug-Induced Dyskinesia
Tunisia
Preventive Medicine
Dopamine Agonists
Dyskinesias
Neurologic Examination
Regression Analysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery

Cite this

A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. / Nishioka, Kenya; Kefi, Mounir; Jasinska-Myga, Barbara; Wider, Christian; Vilariño-Güell, Carles; Ross, Owen A; Heckman, Michael G.; Middleton, Lefkos T.; Ishihara-Paul, Lianna; Gibson, Rachel A.; Amouri, Rim; Yahmed, Samia Ben; Sassi, Samia Ben; Zouari, Mourad; Euch, Ghada El; Farrer, Matthew J.; Hentati, Faycal.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 81, No. 4, 04.2010, p. 391-395.

Research output: Contribution to journalArticle

Nishioka, K, Kefi, M, Jasinska-Myga, B, Wider, C, Vilariño-Güell, C, Ross, OA, Heckman, MG, Middleton, LT, Ishihara-Paul, L, Gibson, RA, Amouri, R, Yahmed, SB, Sassi, SB, Zouari, M, Euch, GE, Farrer, MJ & Hentati, F 2010, 'A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease', Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 4, pp. 391-395. https://doi.org/10.1136/jnnp.2009.185231
Nishioka, Kenya ; Kefi, Mounir ; Jasinska-Myga, Barbara ; Wider, Christian ; Vilariño-Güell, Carles ; Ross, Owen A ; Heckman, Michael G. ; Middleton, Lefkos T. ; Ishihara-Paul, Lianna ; Gibson, Rachel A. ; Amouri, Rim ; Yahmed, Samia Ben ; Sassi, Samia Ben ; Zouari, Mourad ; Euch, Ghada El ; Farrer, Matthew J. ; Hentati, Faycal. / A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. In: Journal of Neurology, Neurosurgery and Psychiatry. 2010 ; Vol. 81, No. 4. pp. 391-395.
@article{d1c1e5179c434dbea3e72b3fbff8e008,
title = "A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease",
abstract = "Genetic classification of Parkinson's disease (PD) subtypes may become the preferred diagnostic tool for neurologists. Herein we compare clinical features from a large cohort of patients with familial PD of unknown aetiology or attributable to distinct genetic forms. Comprehensive neurological examinations were performed in 231 familial PD patients from Tunisia. Analysis was previously performed to screen for mutations in leucine rich repeat kinase 2 (LRRK2), PTEN induced kinase 1 (PINK1) and parkin (PRKN). Clinical features were compared between patients with genetically undefined PD (n107) and those with LRRK2 (n=73) and PINK1 (n42) mutations using regression analyses adjusted for gender, age of onset and disease duration. PRKN cases (n9) were too few for meaningful statistical analysis. In comparison with genetically undefined patients, LRRK2 mutation carriers had more severe motor symptoms (median Unified Parkinson's Disease Rating Scale scores w1.6 times higher, p<0.001), a higher rate of dyskinesia (OR 4.21, p0.002) and use of dopamine agonists (OR 3.64, p<0.001), and less postural tremor (OR 0.21, p<0.001). PINK1 mutation carriers presented an increased rate of drug induced dyskinesia (OR 3.81, p=0.007) and a lower rate of postural tremor (OR 0.16, p<0.001) than genetically undefined patients. As expected, PINK1 patients had younger ages and ages at disease onset, and a longer disease duration compared with LRRK2 mutation carriers and genetically undefined patients. Clinical differences between LRRK2, PINK1 and genetically undefined familial PD appear more pronounced than previously appreciated, and may prove useful in clinical practice. As future therapies are targeted to specific protein abnormalities, identifying the genetic causes and associated clinical and pathological features will determine diagnosis, preventative medicine and drug intervention strategies.",
author = "Kenya Nishioka and Mounir Kefi and Barbara Jasinska-Myga and Christian Wider and Carles Vilari{\~n}o-G{\"u}ell and Ross, {Owen A} and Heckman, {Michael G.} and Middleton, {Lefkos T.} and Lianna Ishihara-Paul and Gibson, {Rachel A.} and Rim Amouri and Yahmed, {Samia Ben} and Sassi, {Samia Ben} and Mourad Zouari and Euch, {Ghada El} and Farrer, {Matthew J.} and Faycal Hentati",
year = "2010",
month = "4",
doi = "10.1136/jnnp.2009.185231",
language = "English (US)",
volume = "81",
pages = "391--395",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease

AU - Nishioka, Kenya

AU - Kefi, Mounir

AU - Jasinska-Myga, Barbara

AU - Wider, Christian

AU - Vilariño-Güell, Carles

AU - Ross, Owen A

AU - Heckman, Michael G.

AU - Middleton, Lefkos T.

AU - Ishihara-Paul, Lianna

AU - Gibson, Rachel A.

AU - Amouri, Rim

AU - Yahmed, Samia Ben

AU - Sassi, Samia Ben

AU - Zouari, Mourad

AU - Euch, Ghada El

AU - Farrer, Matthew J.

AU - Hentati, Faycal

PY - 2010/4

Y1 - 2010/4

N2 - Genetic classification of Parkinson's disease (PD) subtypes may become the preferred diagnostic tool for neurologists. Herein we compare clinical features from a large cohort of patients with familial PD of unknown aetiology or attributable to distinct genetic forms. Comprehensive neurological examinations were performed in 231 familial PD patients from Tunisia. Analysis was previously performed to screen for mutations in leucine rich repeat kinase 2 (LRRK2), PTEN induced kinase 1 (PINK1) and parkin (PRKN). Clinical features were compared between patients with genetically undefined PD (n107) and those with LRRK2 (n=73) and PINK1 (n42) mutations using regression analyses adjusted for gender, age of onset and disease duration. PRKN cases (n9) were too few for meaningful statistical analysis. In comparison with genetically undefined patients, LRRK2 mutation carriers had more severe motor symptoms (median Unified Parkinson's Disease Rating Scale scores w1.6 times higher, p<0.001), a higher rate of dyskinesia (OR 4.21, p0.002) and use of dopamine agonists (OR 3.64, p<0.001), and less postural tremor (OR 0.21, p<0.001). PINK1 mutation carriers presented an increased rate of drug induced dyskinesia (OR 3.81, p=0.007) and a lower rate of postural tremor (OR 0.16, p<0.001) than genetically undefined patients. As expected, PINK1 patients had younger ages and ages at disease onset, and a longer disease duration compared with LRRK2 mutation carriers and genetically undefined patients. Clinical differences between LRRK2, PINK1 and genetically undefined familial PD appear more pronounced than previously appreciated, and may prove useful in clinical practice. As future therapies are targeted to specific protein abnormalities, identifying the genetic causes and associated clinical and pathological features will determine diagnosis, preventative medicine and drug intervention strategies.

AB - Genetic classification of Parkinson's disease (PD) subtypes may become the preferred diagnostic tool for neurologists. Herein we compare clinical features from a large cohort of patients with familial PD of unknown aetiology or attributable to distinct genetic forms. Comprehensive neurological examinations were performed in 231 familial PD patients from Tunisia. Analysis was previously performed to screen for mutations in leucine rich repeat kinase 2 (LRRK2), PTEN induced kinase 1 (PINK1) and parkin (PRKN). Clinical features were compared between patients with genetically undefined PD (n107) and those with LRRK2 (n=73) and PINK1 (n42) mutations using regression analyses adjusted for gender, age of onset and disease duration. PRKN cases (n9) were too few for meaningful statistical analysis. In comparison with genetically undefined patients, LRRK2 mutation carriers had more severe motor symptoms (median Unified Parkinson's Disease Rating Scale scores w1.6 times higher, p<0.001), a higher rate of dyskinesia (OR 4.21, p0.002) and use of dopamine agonists (OR 3.64, p<0.001), and less postural tremor (OR 0.21, p<0.001). PINK1 mutation carriers presented an increased rate of drug induced dyskinesia (OR 3.81, p=0.007) and a lower rate of postural tremor (OR 0.16, p<0.001) than genetically undefined patients. As expected, PINK1 patients had younger ages and ages at disease onset, and a longer disease duration compared with LRRK2 mutation carriers and genetically undefined patients. Clinical differences between LRRK2, PINK1 and genetically undefined familial PD appear more pronounced than previously appreciated, and may prove useful in clinical practice. As future therapies are targeted to specific protein abnormalities, identifying the genetic causes and associated clinical and pathological features will determine diagnosis, preventative medicine and drug intervention strategies.

UR - http://www.scopus.com/inward/record.url?scp=77950613042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950613042&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2009.185231

DO - 10.1136/jnnp.2009.185231

M3 - Article

C2 - 19726410

AN - SCOPUS:77950613042

VL - 81

SP - 391

EP - 395

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 4

ER -